PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS
DOI:
https://doi.org/10.22159/ajpcr.2024v17i8.51398Keywords:
Biopharmaceuticals,, Structural complexity, Formulation development, Regulatory compliance,, Quality by design, Immunogenicity, BioethicsAbstract
Beyond conventional small drug molecules mostly of synthetic origin, clinical benefits have been well established by administering large complex biomolecules against different diseases including cancer, metabolic disorders, and infectious diseases. From insulin, its different derivatives and dosage forms to cutting-edge messenger ribonucleic acid (mRNA) based vaccines, stem cells, immunotherapy with chimeric antigen receptor T cells for cancer likewise offered novel, pivotal pathways in healthcare and helped in alleviating the corresponding diseases, maintaining the overall quality of life of patients. However, the lifecycle management of these biopharmaceuticals offers stern challenges, namely, the structural complexity of biomedicines impacting drug discovery and formulation development, multifaceted manufacturing processes involving living systems (e.g., mammalian cell lines, microbial agents, plants, fungi, etc.), temperature and humidity sensitive supply chain management, stringent regulatory requirements, invasive drug delivery approaches, monitoring immunogenicity after drug administration, etc. Animal and clinical testing of the biologics are also very challenging. Novel biopharmaceuticals including cell-based medicines, recombinant products, gene therapy products, etc. often face ethical and higher cost-related issues. Proper alignment of regulatory guidelines, innovative bioinformatics, and software-based drug discovery tools, implementation of quality by design approaches to identify critical quality parameters at the drug developmental phase, the suitable training to health-care professionals on usage, safety, immunogenicity, handling and storage of biopharmaceuticals would bestow clinical benefits of biopharmaceuticals to the desired patients. Continual research is going on to market new biopharmaceuticals in a cost-effective manner for difficult-to-treat terminal diseases preferably through peroral administration.
Downloads
References
Misra M. Biosimilars: Current perspectives and future implications. Indian J Pharmacol. 2012;44(1):12-14. doi: 10.4103/0253-7613.91859
Leader B, Baca QJ, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39. doi: 10.1038/nrd2399
Leavy O. Therapeutic antibodies: Past, present and future. Nat Rev Immunol. 2010;10(5):297. doi: 10.1038/nri2763
Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol. 2022;40(12):1722-60. doi: 10.1038/s41587-022-01582-x
Kesik‐Brodacka M. Progress in biopharmaceutical development. Biotechnol Appl Biochem. 2018;65(3):306-22. doi: 10.1002/bab.1617
Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, et al. Identification, and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem. 2009;392(2):145-54. doi: 10.1016/j. ab.2009.05.043
Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, et al. Charge variants in IgG1. MAbs. 2010;2(6):613-24. doi: 10.4161/ mabs.2.6.13333
Beck A. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs. 2011;3(2):107-10. doi: 10.4161/mabs.3.2.14785
Weise M. From bioequivalence to biosimilars: How much do regulators dare? Z Evid Fortbild Qual Gesundhwes. 2019;140:58-62. doi: 10.1016/j.zefq.2018.12.001
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biologics, biosimilars, and biobetters: Different terms or different drugs? Eye. 2019;33(7):1032-4. doi: 10.1038/s41433-019-0391-5
Weise M, Bielsky MC, de Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29(8):690-3. doi: 10.1038/nbt.1936
Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. Biodrugs. 2015;9(4):215-39. doi: 10.1007/ s40259-015-0133-6
Kim H, Alten R, Cummings F, Danese S, D’Haens G, Emery P, et al. Innovative approaches to biologic development on the trail of CT-P13: Biosimilars, value-added medicines, and biobetters. MAbs. 2021;13(1):e1868078. doi: 10.1080/19420862.2020.1868078
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437-47. doi: 10.1158/1078- 0432.CCR-11-0762
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91. doi: 10.1056/NEJMoa1209124
IQVIA Consulting Services. Case Studies for Value Added Medicines Unlocking the Potential of Patient-centric Continuous Innovation; 2019. p. 1-57. Available from: https://www.medicinesforeurope.com/ wp-content/uploads/2019/04/iqvia-mfe_case-studies-for-vams_final-word-document_vupdate2019-v3.0.pdf [Last accessed on 2024 May 4].
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-75. doi:10.1016/S0140-6736(17)31585-4
Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, et al. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: Protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study. BMJ Open. 2021;11(5):e047993. doi: 10.1136/bmjopen-2020-047993
Zhao L, Ren T, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012;33(11):1339-47. doi:10.1038/aps.2012.51
Mellstedt H. Clinical considerations for biosimilar antibodies. Eur J Cancer Suppl. 2013;11(3):1-11. doi: 10.1016/S1359-6349(13)70001-6
Chan JC, Chan AT. Biologics and biosimilars: what, why and how? ESMO Open. 2017;2(1):e000180. doi:10.1136/esmoopen-2017-000180
Morrow T, Felcone LH. Defining the difference: What makes biologics unique. Biotechnol Healthc. 2004;1(4):24-9. PMID: 23393437
Ciucci G, Colliva A, Vuerich R, Pompilio G, Zacchigna S. Biologics and cardiac disease: Challenges and opportunities. Trends Pharmacol Sci. 2022;43(11):894-905. doi: 10.1016/j.tips.2022.06.001
Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018;11(6):540-52. doi: 10.1111/cts.12567
Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58. doi: 10.1038/clpt.2008.170
Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies. Clin Pharmacokinet. 2011;50(2):131-42. doi: 10.2165/11537430-000000000-00000
Wang YM, Jawa V, Ma M. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: Scientific considerations for bioanalytical methods and data analysis. Bioanalysis. 2014;6(1):79-87. doi:10.4155/bio.13.302
Medi MB, Chintala R, Akhilesh B. Excipient Selection in Biologics and vaccines Formulation Development. Vol. 19. European Pharmaceutical Review; 2014. p. 16-20. Available from: https://www. europeanpharmaceuticalreview.com/article/24136/excipient-selection-biologics-vaccines-formulation-development [Last accessed on 2024 May 04].
Courtney KN. Key CMC Considerations for Biologic Development. Vol. 24. American Pharmaceutical Review; 2021. Available from: https://www.americanpharmaceuticalreview.com/featured-articles/581696-key-cmc-considerations-for-biologic-development [Last accessed on 2024 May 04].
Weinbuch D, Hawe A, Jiskoot W, Friess W. Introduction into formulation development of biologics. In: Warne N, Mahler HC, editors. Challenges in Protein Product Development. (AAPS Advances in the Pharmaceutical Sciences Series). Cham: Springer; 2018. p. 3-22. doi: 10.1007/978-3-319-90603-4_1
Muralidhara BK, Wong M. Critical considerations in the formulation development of parenteral biologic drugs. Drug Discov Today. 2020;25(3):574-81. doi: 10.1016/j.drudis.2019.12.011
Bajracharya R, Song JG, Back SY, Han HK. Recent advancements in non-invasive formulations for protein drug delivery. Comput Struct Biotechnol J. Sep 2019;17:1290-308. doi: 10.1016/j.csbj.2019.09.004
Ionova Y, Wilson L. Biologic excipients: Importance of clinical awareness of inactive ingredients. PLOS One. 2020;15(6):e0235076. doi: 10.1371/journal.pone.0235076
Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci. 2008;97(8):2924-35. doi: 10.1002/jps.21190
Challener CA. Excipients for high-concentration biologics. Biopharm Int. 2022;35(3):17-37.
Bhambhani A, Kissmann JM, Joshi SB, Volkin DB, Kashi RS, Russell MC. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. J Pharm Sci. 2012;101(3):1120-35. doi: 10.1002/jps.23008
Irvine DJ, Su X, Kwong B. Routes of delivery for biological drug products. In: Wei W, Manmohan S, editors. Biological Drug Products: Development and Strategies. United States: Wiley; 2013. p. 1-48. doi: 10.1002/9780470571224.pse521
Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14(9):844-57. doi: 10.18553/jmcp.2008.14.9.844
Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S, et al. Management of venous port systems in oncology: A review of current evidence. Ann Oncol. 2008;19(1):9-15. doi: 10.1093/ annonc/mdm272
Tetteh EK, Morris S. Evaluating the administration costs of biologic drugs: Development of a cost algorithm. Health Econ Rev. Dec 2014;4(1):26. doi: 10.1186/s13561-014-0026-2
Van Horssen R, Ten Hagen TL, Eggermont AM. TNF-α in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397-408. doi: 10.1634/theoncologist.11-4-397
Grünhagen DJ, de Wilt JH, Ten Hagen TL, Eggermont AM. Technology insight: Utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Rev Clin Oncol. 2006;3(2):94-103. doi: 10.1038/ncponc0426
Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421-34. doi: 10.1016/j.addr.2008.04.012
Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol. 1999;17(8):780-3. doi: 10.1038/11717
Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. Biodrugs. 2009;23(2):93-109. doi: 10.2165/00063030- 200923020-00003
Herrington-Symes AP, Farys M, Khalili H, Brocchini S. Antibody fragments: Prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol. 2013;4(5):689-98. doi: 10.4236/ abb.2013.45090
Badkar AV, Gandhi RB, Davis SP, LaBarre MJ. Subcutaneous delivery of high-dose/volume biologics: Current status and prospect for future advancements. Drug Des Devel Ther. 2021;15:159-70. doi: 10.2147/ DDDT.S287323
Palm T, Eren S, Gandhi R, Khossravi M. The importance of the concentration-temperature-viscosity relationship for the development of biologics. Bioprocess Int. 2015;13:32-4.
Garidel P, Kuhn AB, Schäfer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: How high is high? Eur J Pharm Biopharm. 2017;119:353-60. doi: 10.1016/j.ejpb.2017.06.029
Frost GI. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-40. doi: 10.1517/17425247.4.4.427
Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9(12):1035-50. doi: 10.2217/imt-2017- 0092
Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: Can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6(9):995-1002. doi: 10.1517/17425240903134769
Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2011;63(10):2854-64. doi: 10.1002/art.30463
Kaiser C, Knight A, Nordström D, Pettersson T, Fransson J, Florin- Robertsson E, et al. Injection-site reactions upon Kineret (anakinra) administration: Experiences and explanations. Rheumatol Int. 2012;32(2):295-9. doi: 10.1007/s00296-011-2096-3
Di Cantogno EV, Russell S, Snow T. Understanding and meeting injection device needs in multiple sclerosis: A survey of patient attitudes and practices. Patient Prefer Adherence. 2011;5:173-80. doi: 10.2147/ PPA.S14903
Kuzman D, Bunc M, Ravnik M, Reiter F, Žagar L, Bončina M. Long-term stability predictions of therapeutic monoclonal antibodies in solution using Arrhenius-based kinetics. Sci Rep. 2021;11(1):20534. doi: 10.1038/s41598-021-99875-9
Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: Separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505-23. doi: 10.1080/10837450701481157
Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708-14. doi: 10.1016/j.copbio.2009.10.006
Thomas CR, Geer D. Effects of shear on proteins in solution. Biotechnol Lett. 2011;33(3):443-56. doi: 10.1007/s10529-010-0469-4
Mazzeo A, Carpenter P. Stability studies for biologics. In: Huynh-Ba K, editor. Handbook of Stability Testing in Pharmaceutical Development- Regulations, Methodologies, and Best Practices. New York: Springer Science+Business Media; 2009. p. 353-69. doi: 10.1007/978-0-387- 85627-8_17
Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng. 2002;4(1):155-74. doi: 10.1146/annurev. bioeng.4.092801.094202
Jahn TR, Makin OS, Morris KL, Marshall KE, Tian P, Sikorski P, et al. The common architecture of cross-β amyloid. J Mol Biol. 2010;395(4):717-27. doi: 10.1016/j.jmb.2009.09.039
Riek R, Eisenberg DS. The activities of amyloids from a structural perspective. Nature. 2016;539(7628):227-35. doi: 10.1038/nature20416
Bowerman CJ, Nilsson BL. Review self‐assembly of amphipathic β‐sheet peptides: Insights and applications. Peptide Sci. 2012;98(3):169-84. doi: 10.1002/bip.22058
Trainor K, Broom A, Meiering EM. Exploring the relationships between protein sequence, structure and solubility. Curr Opin Struct Biol. 2017;42:136-46. doi: 10.1016/j.sbi.2017.01.004
Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. doi:10.1098/rsfs.2017.0030
Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-83. doi: 10.1023/B: PHAM.0000033016.36825.2c
Wurth C, Guimard NK, Hecht MH. Mutations that reduce aggregation of the Alzheimer’s Aβ42 peptide: An unbiased search for the sequence determinants of Aβ amyloidogenesis. J Mol Biol. 2002;319(5):1279-90. doi: 10.1016/S0022-2836(02)00399-6
Frokjaer S, Otzen DE. Protein drug stability: A formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306. doi: 10.1038/nrd1695
Krielgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, et al. Effect of tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci. 1998;87(12):1597-603. doi: 10.1021/js980126i
Wang M, Li Y, Srinivasan P, Hu Z, Wang R, Saragih A, et al. Interactions between biological products and product packaging and potential approaches to overcome them. AAPS PharmSciTech. 2018;19(8):3681-6. doi: 10.1208/s12249-018-1184-z
Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454-67. doi: 10.1007/s11095-011-0621-4
Harrison B, Rios M. Big Shot: Developments in Prefilled Syringes. Vol. 31. PharmTech; 2007. p. 50-60. Available from: https://www. pharmtech.com/view/big-shot-developments-prefilled-syringes [Last accessed on 2024 May 04].
Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. Apr 2005;94(4):918-27. doi: 10.1002/ jps.20321
Crommelin DJ, Hawe A, Jiskoot W. Formulation of biologics including biopharmaceutical considerations. In: Crommelin D, Sindelar R, Meibohm B, editors. Pharmaceutical Biotechnology. Cham: SpringerNature Switzerland AG; 2019. p. 83-103. doi: 10.1007/978-3-030- 00710-2_5
Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci. 1997;86(11):1250-5. doi: 10.1021/js970143s
Nguyen TH. Cheminform abstract: Oxidation degradation of protein pharmaceuticals. ChemInform. 1995;p.59-71. doi: 10.1002/ chin.199504314
Janecki DJ, Reilly JP. Denaturation of metalloproteins with EDTA to facilitate enzymatic digestion and mass fingerprinting. Rapid Commun Mass Spectrom. 2005;19(10):1268-72. doi: 10.1002/rcm.1924
Zhou S, Schöneich C, Singh SK. Biologics formulation factors affecting metal leachables from stainless steel. AAPS PharmSciTech. 2011;12(1):411-21. doi: 10.1208/s12249-011-9592-3
Yokota H, Saito H, Masuoka K, Kaniwa H, Shibanuma T. Reversed phase HPLC of Met58 oxidized rhIL-11: Oxidation enhanced by plastic tubes. J Pharm Biomed Anal. 2002;24(2):317-24. doi: 10.1016/S0731- 7085(00)00419-2
Castner J, Benites P, Bresnick M. Leachables and extractables. In: Jameel F, Hershenson S, editors. Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals. New Jersey: John Wiley and Sons; 2010. p. 857-80. doi: 10.1002/9780470595886.ch34
Gronemeyer P, Ditz R, Strube J. Trends in upstream and downstream process development for antibody manufacturing. Bioengineering. 2014;1(4):188-12. doi: 10.3390/bioengineering1040188
Tripathi NK, Shrivastava A. Recent developments in bioprocessing of recombinant proteins: Expression hosts and process development. Front Bioeng Biotechnol. 2019;7:420. doi: 10.3389/fbioe.2019.00420
Roch P, Mandenius CF. On-line monitoring of downstream bioprocesses. Curr Opin Chem Eng. 2016;14:112-20. doi: 10.1016/j. coche.2016.09.007
Azevedo AM, Rosa PA, Ferreira IF, Aires-Barros MR. Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing. Trends Biotechnol. 2009;27(4):240-7. doi: 10.1016/j. tibtech.2009.01.004
Rathore AS, Kapoor G. Application of process analytical technology for downstream purification of biotherapeutics. J Chem Technol Biotechnol. 2015;90(2):228-36. doi: 10.1002/jctb.4447
Sarkis M, Bernardi A, Shah N, Papathanasiou MM. Emerging challenges and opportunities in pharmaceutical manufacturing and distribution. Processes. 2021;9(3):457. doi: 10.3390/pr9030457
Szkodny AC, Lee KH. Biopharmaceutical manufacturing: Historical perspectives and future directions. Annu Rev Chem Biomol Eng. 2022;13(1):141-65. doi: 10.1146/annurev-chembioeng-092220-125832
Ter Horst JP, Turimella SL, Metsers F, Zwiers A. Implementation of quality by design (QbD) principles in regulatory dossiers of medicinal products in the European Union (EU) between 2014 and 2019. Ther Innov Regul Sci. 2021;55(3):583-90. doi: 10.1007/s43441-020- 00254-9
Rathore AS. QbD/PAT for bioprocessing: Moving from theory to implementation. Curr Opin Chem Eng. 2014;6:1-8. doi: 10.1016/j. coche.2014.05.006
Eon‐Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28(3):608-22. doi: 10.1002/btpr.1548
Rathore AS. Quality: Design space for biotech products. Biopharm Int. 2007;20(4):40-5.
Rathore AS, Singh SK, Kumar J, Kapoor G. Implementation of QbD for manufacturing of biologics-has it met the expectations? In: Jagschies G, Lindskog E, Łącki K, Galliher P, editors. Biopharmaceutical Processing - Development, Design and Implementation of Manufacturing Processes. Amsterdam: Elsevier; 2018. p. 1051-73. doi:10.1016/B978-0-08-100623-8.00048-7
Kozlowski S, Swann P. Considerations for biotechnology product by design. In: Rathore AS, Mhatre R, editors. Quality by Design for Biopharmaceuticals: Principles and Case Studies. New Jersey: John Wiley and Sons Inc.; 2009. p. 9-30. doi: 10.1002/9780470466315.ch2
Kelley B. Quality by Design risk assessments supporting approved antibody products. MAbs. 2016;8(8):1435-6. doi: 10.1080/19420862.2016.1232218
Kokil S, Singh S. Current perspective on opportunities and adoption challenges of QbD implementation in pharmaceutical product development. Invent Rapid Pharm Process Dev. 2016;2:1-8.
Milmo S. Quality by design bridging the gap between concept and implementation. Biopharm Int. 2014;29(4):40-5.
Sykes C. Time-and temperature-controlled transport: Supply chain challenges and solutions. P T. 2018;43(3):154-70. PMID: 29491697
Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener- Hooker N, Shah N. Autologous CAR T-cell therapies supply chain: Challenges and opportunities? Cancer Gene Ther. 2020;27(10-1):799- 809. doi: 10.1038/s41417-019-0157-z
Ned P, Lopez E. Top challenges facing drug supply chains. Biopharmdrive; 2018. Available from: https://www.biopharmadive. com/news/top-challenges-facing-drug-supply-chains/521876 [Last accessed on 2024 May 04].
Jaffer G. Pharma’s Almanac. Keys to Successful Storage, Management and Transport of Biological Materials; 2020. Available from: https:// www.pharmasalmanac.com/articles/keys-to-successful-storage-management-and-transport-of-biological-materials [Last accessed on 2024 May 04].
Tetz A. The Evolution of Smart Temperature-controlled Packaging. Packaging Europe; 2017. Available from: https://packagingeurope. com/the-evolution-of-smart-temperature-controlled-packaging/2958. article [Last accessed on 2024 May 04].
Ibrahim T, Araujo CA. Biopharmaceutical supply chain challenges in developing countries: an exploratory analysis. Suppl Chain Forum Int J. 2021;22(4):294-309. doi: 10.1080/16258312.2021.1936152
Zobel A, Heelan B. Regulatory, Clinical and Logistics Challenges of Advanced Therapy Medicinal Products (ATMPs) in clinical research. European Pharmaceutical Review; 2017. Available from: https://www. europeanpharmaceuticalreview.com/article/81122/regulatory-clinical-and-logistics-challenges-of-advanced-therapy-medicinal-products-atmps-in-clinical-research [Last accessed on 2024 May 04].
Penugonda VL, Cherukuri VP, Vaka NS, Juturi RK. Development of biosimilars: An overview of the regulatory framework in India, USA, EU; major challenges and related case studies. Int J Pharm Sci Res. 2021;12(12):6341-52. doi: 10.13040/IJPSR.0975-8232.12(12).6341-52
Chisholm O, Critchley H. Future directions in regulatory affairs. Front Med. 2023;9:1082384. doi: 10.3389/fmed.2022.1082384
Druedahl LC, Almarsdóttir AB, Sporrong SK, De Bruin ML, Hoogland H, Minssen T, et al. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nat Biotechnol. 2020;38(11):1253-56. doi: 10.1038/s41587- 020-0717-7
Lokesh C, Sonia K, Kamaraj R. Regulatory requirements for biological product approval process in India. Res J Pharm Technol. 2020;13(2):1050-4. doi: 10.5958/0974-360X.2020.00193.6
Senior M. Fresh from the biotech pipeline: Fewer approvals, but biologics gain share. Nat Biotechnol. 2023;41(2):174-82. doi: 10.1038/ s41587-022-01630-6
Sekhon BS, Saluja V. Biosimilars: An overview. Biosimilars 2011;1:1- 11. doi: 10.2147/BS.S16120
Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics, and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem. 2012;3(4):73-92. doi: 10.4331/ wjbc.v3.i4.73
Wang J, Iyer S, Fielder PJ, Davis JD, Deng R. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: Comparative evaluation of prediction approaches in early drug development. Biopharm Drug Dispos. 2016;37(2):51-65. doi: 10.1002/ bdd.1952
Acri KM, Lybecker N. Biologics and Biosimilars: A Primer. Fraser Institute; 2020. Available from: https://www.fraserinstitute.org/sites/ default/files/biologics-and-biosimilars-a-primer.pdf [Last accessed on 2024 May 04].
Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26(9):985-90. doi: 10.1038/nbt0908-985
Negrusz-Kawecka M. The role of TNF-alpha in the etiopathogenesis of heart failure. Pol Merkur Lekarski. 2002;12(67):69-72. PMID: 11957809
Friganović A, Mędrzycka-Dąbrowska W, Krupa S, Oomen B, Decock N, Stievano A. Nurses’ knowledge and attitudes towards biosimilar medicines as part of evidence-based nursing practice-international pilot study within the project biosimilars nurses guide version 2.0. Int J Environ Res Public Health. 2022;19(16):10311. doi: 10.3390/ijerph191610311
Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33(12):2160-72. doi: 10.1007/ s12325-016-0431-5
Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: A systematic review. J Manag Care Spec Pharm. 2019;25(1):102-12. doi: 10.18553/jmcp.2019.25.1.102
Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: A Belgian case study. Pharmacoeconomics. 2014;32(7):681-91. doi: 10.1007/s40273-014-0163-9
Pasina L, Casadei G, Nobili A. A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016;35:e31-3. doi: 10.1016/j.ejim.2016.07.010
O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252-61. doi: 10.1016/j.yrtph.2017.06.013
Adé A, Bourdon O, Bussières JF. A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France. Ann Pharm Fr. 2017;75(4):267-75. doi: 10.1016/j.pharma.2017.01.003
Gahlot P, Dhankhar R, Yadav P, Vigarniya MM. Challenges of biomedical waste management. Ann Biol. 2019;35(2):191-200.
Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655-72. doi: 10.1038/nrd4363
Baumann A. Preclinical development of therapeutic biologics. Expert Opin Drug Discov. 2008;3(3):289-97. doi: 10.1517/17460441.3.3.289
Baumann A. Nonclinical development of biopharmaceuticals. Drug Discov Today. 2009;14(23-4):1112-22. doi: 10.1016/j. drudis.2009.09.013
Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals. Drug Saf. 2010;33(10):865-78. doi: 10.2165/11538330-000000000-00000
Ryan AM. Frontiers in nonclinical drug development. Vet Pathol. 2015;52(2):419-26. doi: 10.1177/0300985814547282
DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20(11):1885-900. doi: 10.1023/B: PHAM.0000003390.51761.3d
Bareham B, Georgakopoulos N, Matas-Céspedes A, Curran M, Saeb- Parsy K. Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies. Cancer Immunol Immunother. 2021;70:2737-50. doi: 10.1007/s00262-021-02897-5
Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and neck cancer immunotherapy: Molecular biological aspects of preclinical and clinical research. Cancers. 2023;15(3):852. doi: 10.3390/cancers15030852
Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FD. 3D cell culture systems: Advantages and applications. J Cell Physiol. 2015;230(1):16-26. doi: 10.1002/jcp.24683
Belfiore L, Aghaei B, Law AM, Dobrowolski JC, Raftery LJ, Tjandra AD, et al. Generation and analysis of 3D cell culture models for drug discovery. Eur J Pharm Sci. 2021;163:105876. doi: 10.1016/j. ejps.2021.105876
Moysidou CM, Barberio C, Owens RM. Advances in engineering human tissue models. Front Bioeng Biotechnol. 2021;8:620962. doi: 10.3389/fbioe.2020.620962
Freires IA, Morelo DF, Soares LF, Costa IS, de Araújo LP, Breseghello I, et al. Progress and promise of alternative animal and non-animal methods in biomedical research. Arch Toxicol. 2023;97(9):2329-42. doi: 10.1007/s00204-023-03532-1
Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952-5. doi: 10.1126/science. aaw6985
Belair DG, Visconti RJ, Hong M, Marella M, Peters MF, Scott CW, et al. Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs. Toxicol In Vitro. 2020;68:104928. doi: 10.1016/j.tiv.2020.104928
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001
Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478. doi: 10.3389/fgene.2019.00478
Catenacci DV. Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967-96. doi: 10.1016/j.molonc.2014.09.011
Published
How to Cite
Issue
Section
Copyright (c) 2024 Sayon Paul, Avik Sarkar
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
